Dr. Scott T. Guenthner, MD

Medicare patients and services

Medicare patients, 2024

1,562

Services billed

9,401

Patients’ average age

75

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 28 companies reported 540 payments worth $493,979 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Indiana →

Industry-funded research

Named as a principal investigator on 29 industry-funded studies in 2025, from 13 companies. The companies reported $1,201,071 in research payments for these studies, mostly to the institutions running them.

• Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
  Eli Lilly and Company · Completed · NCT06588283
• Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp
  Biofrontera Inc. · Completed · NCT05662202
• Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
  Sun Pharmaceutical Industries Inc.
• A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who Are Inadequately Contro…
  Amgen Inc.
• A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis
  Sun Pharmaceutical Industries Inc.
• Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis
  AbbVie Inc. · Completed · NCT05969223
• A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASC…
  Amgen Inc.
• A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
  UCB SA · Completed · NCT04901195
• Open-label phase i study to evaluate the pharmacokinetics of 5-aminolevulinic acid and protoporphyrin ix in human plasma under maximal use conditions after topical application of 3 tubes of BF-200 ala to a treatment f…
  Biofrontera Inc.
• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affec…
  Janssen Research & Development, LLC

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Dermatology clinicians in Greenwood

• Maria C. Bell
• Christopher M. Bohyer, M.D.
• Ryan K. Brashear, M.D.
• Thomas J. Eads, MD
• Andrew J. Scripture, MD
• Laura T. Stitle, MD
• Honglin Xiao